drugset / Trial / NCT06535841
A First-in-Human Safety Trial of MTX-474
RandomizedParallel-groupTriple-blindOther
Summary
A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-474 administered in healthy adults.
Timeline
- Start
- 2024-07-10
- Primary completion
- 2025-04-24
- Completion
- 2025-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MTX-474 | Monoclonal antibody | 0.125 mg/kg | — |
| Subject | MTX-474 | Monoclonal antibody | 0.25 mg/kg | — |
| Subject | MTX-474 | Monoclonal antibody | 0.5 mg/kg | — |
| Subject | MTX-474 | Monoclonal antibody | 1 mg/kg | — |
| Subject | MTX-474 | Monoclonal antibody | 2 mg/kg | — |
| Subject | MTX-474 | Monoclonal antibody | 4 mg/kg | — |
Indications
No indication recorded.